RxDoctor Payments DataLook up a doctor →

Kelly Gollar, APRN

Nurse Practitioner · Jeffersonville, INNPI 1548257637

Payments from drug & device makers

$11,322in general payments, 2019–2025

Across 415 payments — averaging $27.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$1K
  • Pfizer$1K
  • Johnson & Johnson$1K
  • Medtronic$888
  • Astellas Pharma US Inc$855
  • Bayer$794
  • plus $5K from 34 others

What the payments were for

  • Consulting fees$3903%
  • Speaking & faculty fees$1,52313%
  • Food & beverage$8,94979%
  • Education$4594%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,322 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$148,416
Medicare patients
1,211
Services billed
4,459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron60$61,221
GemtesaVibegron85$56,813
Tamsulosin Hcl575$8,975
Estradiol65$3,771
Finasteride150$1,679
Solifenacin Succinate14$1,405
Alfuzosin Hcl ErAlfuzosin Hcl77$1,282
Potassium Citrate ErPotassium Citrate18$1,184
Trimethoprim18$1,161
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst76$1,079
Oxybutynin Chloride ErOxybutynin Chloride14$1,070
Oxybutynin Chloride22$804
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim109$706
Doxycycline Monohydrate29$548
Cephalexin43$503

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$855$61,22160 claims
Sumitomo Pharma America, Inc.Gemtesa$225$56,81385 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Jeffersonville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →